CEO, PRESIDENT, RXSIGHT
WHY: Oversees Aliso Viejo firm that commercialized the world’s first and only adjustable intraocular lens that is customized after cataract surgery. About 80% of customers have 20/20 vision afterward, “much higher” than competing products, notes Kurtz, with the new eyesight lasting a lifetime.
BY THE NUMBERS: The company believes its product could cause a paradigm shift in the industry of cataract surgery, the most common surgical procedure in the world, with approximately 22 million performed in 2020, including 3.7 million in the U.S. Physical footprint has expanded from 5,000 square feet to 117,000 square feet spread among four buildings in Aliso Viejo.
FUTURE PLANS: The company reported sales more than doubled to $49 million in 2022. It’s forecasted revenue this year will climb another 59% to 69%, to $78 million to $83 million. Kurtz has a simple explanation for the sales growth. “At its core, it’s the benefits of the technology,” Kurtz told the Business Journal. “As more people learn and see the result, that leads to growth and interest in the technology.”
IN THEIR WORDS: “There aren’t any other companies that have developed this technology. As far as we know, no other company has even begun clinical trials.”
